Skip to Content

mutNPM1 status is a prognostic and an independent predictive marker for improved survival with azacitidine

Patients with mutNPM1 who received azacitidine have an improved survival of more than 2.5 years compared to placebo compared to a survival gain of all patients in the study of 9.9 months. This indicates that mutNPM1 status is both a prognostic and an independent predictive marker for improved survival with azacitidine.

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top